Landmark Evidence in Nuclear Medicine
The trials that define practice, what each changed, and where judgment remains
Quick Answer
Modern nuclear medicine — and especially theranostics — rests on a defined body of randomized and pivotal evidence. Knowing the trials is not trivia: each answers why a practice is standard, for whom, and — as importantly — where the data stop. This page organizes the field's landmark evidence by domain, stating what each trial changed and the nuance or controversy an expert still weighs. It is the counterpart to the thresholds page: numbers tell you the cutoff, trials tell you whether the cutoff earns its authority.
Prostate — PSMA Theranostics & Bone-Targeted Therapy
| Trial | Contribution | Nuance |
|---|---|---|
| proPSMA (Hofman, Lancet 2020) | PSMA-PET/CT superior to CT + bone scan for staging high-risk disease | Changed management substantially; superiority is in accuracy, not (yet) survival |
| VISION (Sartor, NEJM 2021) | ¹⁷⁷Lu-PSMA-617 improved OS/rPFS in post-ARPI, post-taxane PSMA-positive mCRPC | Required PSMA-positivity by imaging; FDG-discordant disease excluded |
| TheraP (Hofman, Lancet 2021) | ¹⁷⁷Lu-PSMA vs cabazitaxel — higher PSA response, fewer grade 3–4 events | Randomized comparative-effectiveness, not powered primarily for OS |
| PSMAfore (Morris, 2023) | Benefit in taxane-naïve, post-ARPI mCRPC | Supported label expansion; crossover complicates OS interpretation |
| ALSYMPCA (Parker, NEJM 2013) | ²²³Ra improved OS in symptomatic bone-only mCRPC | Bone-microenvironment therapy; PSA unreliable as response marker |
| ERA-223 (Smith, Lancet Oncol 2019) | Ra-223 + abiraterone/prednisone → more fractures/deaths | Avoid the combination; ensure bone-health agents |
The prostate story is the template: image the target (proPSMA/PSMA-RADS) → select and treat (VISION/PSMAfore) → sequence carefully (ALSYMPCA/ERA-223), with FDG flagging the disease that escapes.
Neuroendocrine — PRRT & Antiproliferative Therapy
| Trial | Contribution | Nuance |
|---|---|---|
| NETTER-1 (Strosberg, NEJM 2017) | ¹⁷⁷Lu-DOTATATE prolonged PFS in progressive midgut NET after SSA | Landmark PRRT registration; QoL benefit (2018 approval) |
| NETTER-2 (Singh, Lancet 2024) | ¹⁷⁷Lu-DOTATATE first-line in grade 2–3 GEP-NET | Extends PRRT earlier and to higher grade |
| PROMID / CLARINET | Somatostatin analogs are antiproliferative (not just symptomatic) | Established the SSA backbone |
| RADIANT | Everolimus PFS benefit across GEP-NET | mTOR option in the sequencing algorithm |
Thyroid — De-escalation & RAI-Refractory Systemic Therapy
| Trial | Contribution | Nuance |
|---|---|---|
| HiLo / ESTIMABL1 | 30 mCi non-inferior to 100 mCi for low/intermediate-risk ablation | Drove activity de-escalation; rhTSH equivalent to withdrawal |
| ESTIMABL2 / IoN | Ablation can be omitted in selected low-risk patients | The frontier of de-escalation |
| DECISION / SELECT | Sorafenib / lenvatinib improve PFS in RAI-refractory DTC | Where escalating I-131 stops helping — pivot to systemic therapy |
Liver-Directed — Y-90 Radioembolization
| Trial | Contribution | Nuance |
|---|---|---|
| DOSISPHERE-01 (Garin, 2021) | Personalized dosimetry improved response vs standard in HCC | ~120 Gy (glass) tumor threshold; dosimetry matters |
| LEGACY (Salem, 2021) | Radiation segmentectomy — high, durable local control in early HCC | Curative-intent, parenchyma-sparing |
| SARAH / SIRveNIB | Y-90 vs sorafenib in advanced HCC — not superior for OS | Positioned Y-90 by selection, not as a blanket alternative |
| SIRFLOX / FOXFIRE | Added Y-90 to first-line chemo in colorectal liver mets — no OS benefit | Reserves Y-90 for selected liver-dominant, chemorefractory disease |
Lymphoma — Response-Adapted Therapy
| Trial | Contribution | Nuance |
|---|---|---|
| RATHL (Johnson, NEJM 2016) | Interim-PET-negative Hodgkin can omit bleomycin | De-escalation by Deauville response |
| H10 / PETAL | Interim PET guides escalation/de-escalation (HL and aggressive NHL) | Thresholds and actions are protocol-specific |
Lung — Staging & Futility Reduction
| Trial | Contribution | Nuance |
|---|---|---|
| PLUS (van Tinteren, Lancet 2002) / Fischer (NEJM 2009) | PET-based staging reduces futile thoracotomy | PET-positive mediastinum still needs pathologic confirmation |
Cardiac — Ischemia, Viability, Innervation, Amyloid
| Trial | Contribution | Nuance |
|---|---|---|
| ISCHEMIA (Maron, NEJM 2020) | In stable CAD, routine invasive strategy did not reduce events vs OMT | Reframes how ischemia burden should drive management |
| STICH viability substudy (2011) | Viability marked higher-survival patients but did not independently predict CABG benefit | Viability informs, does not dictate, revascularization |
| ADMIRE-HF | Low cardiac ¹²³I-MIBG H/M ratio is prognostic in heart failure | Threshold is collimator-dependent |
| ATTR-ACT (Maurer, NEJM 2018) | Tafamidis improved survival in ATTR-CM | Made accurate PYP diagnosis actionable |
Selected Other Domains
| Trial / evidence | Contribution |
|---|---|
| PET-NECK (Mehanna, NEJM 2016) | 12-week post-chemoradiation PET-guided surveillance vs planned neck dissection in HNSCC |
| SEMPET (De Santis, JCO 2004) | FDG for post-chemo residual seminoma (> 3 cm, ≥ 6 weeks) |
| MSLT-I / MSLT-II | Sentinel-node status prognostic in melanoma; limited role of completion dissection |
| ZIRCON (Shuch, Lancet Oncol 2024) | ⁸⁹Zr-girentuximab (CAIX) characterizes indeterminate renal masses as ccRCC |
| GiACTA (Stone, NEJM 2017) | Tocilizumab (IL-6) steroid-sparing in GCA |
| NETTER / VISION analogues | Establish the general theranostic template across targets |
How an Expert Reads This
The theranostic domains share one logic proven across trials: image the target to select (proPSMA, NETTER SSTR-PET, ZIRCON), treat with the paired isotope (VISION, NETTER-1/2), and respect where the evidence stops — VISION required imaging positivity and excluded FDG-discordant disease; NETTER selected SSTR-avid disease; ALSYMPCA treated bone-only disease. The trial defines the population, not just the drug.
Several landmark results are negative or reframing, and matter as much as the positive ones: ISCHEMIA (burden alone does not mandate revascularization), the STICH viability substudy (viability informs, not dictates), SARAH/SIRveNIB and SIRFLOX/FOXFIRE (Y-90 is a selection therapy, not a blanket one), and ERA-223 (a harmful combination). Expertise is knowing these as well as the wins.
The thyroid trials (HiLo/ESTIMABL/IoN → DECISION/SELECT) encode a two-sided lesson: de-escalate where more activity adds toxicity without benefit (low-risk ablation, omission), and switch modality where the target is lost (RAI-refractory → multikinase/redifferentiation). The same "know when to stop escalating the same therapy" principle recurs in prostate, NET, and liver disease — the through-line of evidence-based nuclear oncology.
Related Pages
- Reference: Quantitative thresholds & decision cutoffs, oncology response criteria (RECIST/PERCIST), disease/therapy pages linked from each trial.
- Foundational: Molecular imaging & the theranostic pair.
Figure / Diagram Suggestions
- A trial-by-domain timeline (image → select → treat → sequence).
- A positive vs reframing/negative two-column evidence map.
Self-Check
Q1. VISION established ¹⁷⁷Lu-PSMA-617's survival benefit — in which population, and what imaging condition was required?
Answer: PSMA-positive mCRPC after ARPI and taxane, with disease that was PSMA-positive on imaging and not dominated by FDG-discordant (PSMA-negative) disease.
Q2. How did the STICH viability substudy qualify the use of viability imaging?
Answer: Viability identified higher-survival patients but did not independently predict a CABG benefit over medical therapy — viability informs, it does not dictate, the revascularization decision.
Q3. What do HiLo/ESTIMABL and DECISION/SELECT together teach about radioiodine in thyroid cancer?
Answer: De-escalate where more activity adds toxicity without benefit (30 mCi non-inferior; omission in low-risk), and switch to systemic therapy (sorafenib/lenvatinib) when disease becomes RAI-refractory.
Q4. Why are SARAH/SIRveNIB and SIRFLOX/FOXFIRE important despite not showing an OS benefit?
Answer: They define Y-90 radioembolization as a selection therapy (liver-dominant/chemorefractory disease, downstaging, segmentectomy) rather than a blanket alternative to systemic therapy — a negative result that shapes appropriate use.
Evidence & sources
https://nuc.med/landmark-evidence/ Report an issue